Vertex and orphan drugs test limits of US payers
Vertex's cystic fibrosis drugs are among the most expensive ever evaluated by the US Institute for Clinical and Economic Research.
Solving the incremental innovation dilemma
Could pricing pressure lead to the end of incremental innovation – and why does this matter?
As US hospitals consolidate their pharmacy muscles grow
Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.
Biotech gets creative about the pay cheque
Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.
European approvals face delay from agency move
How the EMA's move out of London could impact European drug approvals.
Looking beyond factors in haemophilia
Next-generation projects, including gene therapies, could soon be shaking up the haemophilia market.
Does Roche have the haemophilia X factor?
Experts expect Roche's Hemlibra to dominate the inhibitor patient population, but to be a big deal it will need to impress in non-inhibitor patients, too.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.